12 Clement-Jones V, Lowry PJ, Rees To test the suggestion that chlorpropamide-alcohol flushing (CPAF) resembles the disulfiram effect and might be mediated by acetaldehyde, the initial metabolite of alcohol, blood concentrations of acetaldehyde were measured after a drink of alcohol in controls and diabetics positive and negative for CPAF. The CPAFpositive diabetics had significantly greater blood acetaldehyde concentrations after alcohol than the CPAFnegative diabetics both with a single dose of chlorpropamide and after two weeks' chlorpropamide treatment. Concentrations in the CPAF-positive group after chlorpropamide were also significantly greater than after a placebo tablet. There was also a clear separation in the increase in facial temperature after two weeks of chlorpropamide between the CPAF-positive and CPAFnegative groups (although there was some overlap after a single tablet). There was no difference in plasma chlorpropamide or alcohol concentrations between CPAFpositive and CPAF-negative diabetics.
These findings show that CPAF is distinct from alcohol flushing and that the acetaldehyde concentration in the blood provides an objective measure of CPAF. The difference between flushing and non-flushing diabetics cannot be accounted for by differences in blood concentrations of chlorpropamide or alcohol.
Introduction
Many non-insulin-dependent diabetics treated with chlorpropamide show facial flushing after taking a small quantity of alcohol-chlorpropamide-alcohol flushing (CPAF).' 2 We have previously suggested that CPAF is inherited2 3 and that it may provide clues to the causes of non-insulin-dependent diabetes.4
In 1962 FitzGerald et al suggested that CPAF might be a disulfiram-like reaction mediated by acetaldehyde, the intermediate metabolite of alcohol.' Using the relatively insensitive methods of those days they found no significant difference in acetaldehyde concentrations in CPAF-positive and CPAFnegative diabetics. Recently a sensitive and precise method for assaying of acetaldehyde has been described using head-space gas chromatography.5 Jerntorp et al have reported that during CPAF testing flushers show much higher acetaldehyde concentrations than non-flushers-indeed that there is a clear separation between the two groups.6 It has also been suggested that CPAF-positive subjects (flushers) have higher concentrations of chlorpropamide than those who are CPAF negative (nonflushers).7
We measured blood concentrations of acetaldehyde during CPAF testing in controls and diabetics positive and negative for CPAF after (a) placebo, (b) a single tablet of chlorpropamide, and (c) two weeks' chlorpropamide treatment. We also measured chlorpropamide and alcohol concentrations.
curves prepared by adding ethanol or acetaldehyde to a precipitated plasma suspension.
The coefficient of variation of the acetaldehyde assay for replicate aqueous standards at a concentration range of 1 1-23 ,tmol/l (0 05-1 mg/i) was 7%O. The coefficient of variation for 90 duplicate blood samples, which had a mean acetaldehyde concentration in a diluted plasma suspension of 2-3 ,Lmol/l (0 1 mg/l), was 17%. All results are expressed as means ± SEM and were compared using the Wilcoxon U test for unpaired data.
Results
All subjects had normal liver function values (including y-glutamyl transferase, alkaline phosphatase, and aspartate aminotransferase).
Patients and methods
Twenty-one non-insulin-dependent diabetics -11 CPAF positive (flushers) and 10 CPAF negative (non-flushers)-and 10 non-diabetics were studied. CPAF status in the diabetics had been assessed subjectively as previously described before the study started.2 None had taken chlorpropamide for at least three weeks.
The mean (± SEM) ages (59 ±3, 64±2 respectively) and duration of diabetes (10 ±2, 10±2 years) were similar in the diabetics positive and negative for CPAF. The mean age of the controls was less (46 ± 3). There were eight men and three women in the CPAF-positive group and seven men and three women in the CPAF-negative group.
On day 1, after an overnight fast, blood was taken for liver function tests, and 250 mg chlorpropamide was then given by mouth. After 11 hours a temperature probe was connected to each subject 2 cm below the outer canthus of the eye. After at least 45 minutes' stabilisation duplicate samples of blood were taken for measuring acetaldehyde and alcohol concentrations; 9 ml of 90% alcohol in orange juice was then given and facial temperature was recorded for a further 40 minutes. Blood acetaldehyde and alcohol concentrations were again measured in duplicate 25 minutes after the alcohol challenge. Blood was also taken at 0, 3, 6, 9, 12, 24, 48, 72, and 96 hours for measuring plasma chlorpropamide concentrations.
On day 5 the CPAF-positive diabetics were started on a two-week course of either placebo or chlorpropamide 250 mg daily in a randomised single-blind fashion, and after a further two weeks off treatment they were switched to the other drug. At the end of each period the alcohol challenge test was repeated as on day 1. The CPAF-negative diabetics had a two-week course of chlorpropamide but not placebo. The controls had a placebo test but did not receive the two-week course of chlorpropamide because of the risk of hypoglycaemia.
Plasma chlorpropamide was measured by gas-liquid chromatography. ' Blood alcohol and acetaldehyde concentrations were measured by head-space gas chromatography. Samples were prepared for assay of acetaldehyde by the method of von Wartburg and Ris.5 After incubation at 60°C for 30 minutes 1 ml of head space was injected on to a capillary column 100 m x 07 mm coated with Carbowax 400 and maintained at a temperature of 55°C; the carrier gas was nitrogen and the flow rate 20 ml/min. Alcohol and acetaldehyde were measured by a flame ionisation detector by calculating the ratio of their peak heights to that of the n-propanol internal standard, and using calibration Acetaldehyde levels Before alcohol challenge blood acetaldehyde concentrations were undetectable (< 11 ,mol/l (0-05 mg/i)) in all subjects. After alcohol the results were as follows (fig 1) . After placebo-The CPAF-positive group had acetaldehyde concentrations (23 ±07 ,±mol/l (010±003 mg/i) n= 10) similar to those of the non-diabetic controls (2 5 ±0 5 ,umol/l (0 11±0-02 mg/i)).
After one day's chlorpropamide-The flushers showed a significantly higher concentration of acetaldehyde (104 ±29 lsmol/l (0-46±0-13 mg/i), n = 10) after a single tablet of chlorpropamide than they had shown after the placebo tablet (p < 0 01) and than that shown by the non-flushers (32±07 ismol/l (014±003 mg/i); p<002) and the controls (3 9 ±0 7 ,umol/l (0 17 ±0-03 mg/l) p < 0-02). After two weeks' chlorpropamide-The CPAF-positive group showed a higher blood acetaldehyde value (11-8±2-0 t±mol/l (0 52±0 09 mg/l), n=10) after two weeks' chlorpropamide than after a single tablet, and this was significantly greater than the value in the CPAFnegative group (2-9 ±07 ,imol/l (0 13 ±003 mg/l), n= 9; p <0-01).
Facial temperature
After a single tablet of chlorpropamide the mean increase in facial temperature was greater in the CPAF-positive subjects than in the CPAF-negative subjects (1-6 ±0 2 v 0 6 ±0 1°C respectively; p < 0.01), but there was some overlap between them (fig 2) . After two weeks' chlorpropamide treatment there was no difference in the temperature rise in the CPAF-negative cases (0-6±0 1°C, n=9), but the mean in t the CPAF-positive group rose to 2 3 X 0 3 C. Furthermore, there was no overlap between the two groups: no CPAF-negative case exceeded 1 DC and none of the CPAF-positive cases showed a rise of less than 1 40C. Chilorpropamide concentrati'ons There was no difference in chlorpropamide concentration at any time between the two groups of diabetics after a single tablet or after two weeks of chlorpropamide treatment: mean plasma chlorpropamide concentrations in CPAF-positive and CPAF-negative groups at 12 hours were 58d9±8c7 temol/l (16a3±2l4) and 618t p90 (imol/I (17c1lop2p5 mg/1) respectively) and at two weeks 331±387 smol/I (91-7±10-7) and 283145-6~tmol/l (78-3 12-6 mg/1).
Alcohol conicentrations
There was no significant difference in the blood alcohol concentration in the three groups when they were tested 25 minutes after the drink of alcohol and 12 hours after a single tablet of chlorpropamide. Mean values for the CPAF-positive, CPAF-negative, and control groups were 1 1-1t0 26, 1 08 0-19, 0-91+0-1 mmol/l respectively (51 1:2, 50 09, and 42 +05 mg/100 ml).
Discussion
Flushing after alcohol in patients taking chlorpropamide was first reported within a few months of the introduction of chlorpropamide treatment.9 Clinically the reaction is obvious to the patient and observer. Because testing with a single tablet of chlorpropamide followed by alcohol2 has given varying results,10 11 an objective measure of the phenomenon would be useful, and it now seems that the blood acetaldehyde concentration is such a measure. CPAF-positive diabetics showed a greater increase than CPAF-negative diabetics or controls, and although we did not find such a clear separation into two groups as Jerntorp et a16 there was nearly complete division at 6-8 Ftmol (0 3 mg/l): after two weeks' chlorpropamide no CPAF-negative subjects exceeded this value whereas all but two of the CPAFpositive cases did so.
Some patients who do not flush at 12 hours after a single dose of chlorpropamide do so after two weeks. Our previous suggestion that a single tablet would be adequate for CPAF testing is thus not always true. To be sure whether a person shows CPAF several days' pre-treatment with chlorpropamide is necessary. This will not convert a non-flusher into a flusher but it will expose all those who flush.
Clinically, CPAF is not the same as simple alcohol flushing. Furthermore, the response of CPAF-positive diabetics to alcohol alone, in terms of increase in temperature and acetaldehyde, is the same as in the CPAF-negative groups. The difference between CPAF-positive and CPAF-negative patients is seen only after chlorpropamide administration and cannot be accounted for by differences in chlorpropamide and alcohol concentrations. Our findings show unequivocally that the pharmacokinetics of chlorpropamide are similar in flushers and non-flushers, both after single doses and during multiple dosing, in contrast to the suggestion of Jerntorp et al.7 The concentration of chlorpropamide in blood that will elicit the CPAF response varies: one CPAF-positive diabetic had a rise in facial temperature of 1 5°C and an acetaldehyde concentration of 16 3 ,tmol/l (0-72 mg/l) with a chlorpropamide concentration of 14 8 pmol/l (4-1 mg/l) whereas another patient had values of 1 4°C and 7-5 kmol/l (0 33 mg/l) respectively with a plasma chlorpropamide concentration of 76 3 ,tmol/l (21-1 mg/i).
Acetaldehyde is formed from alcohol predominantly via the alcohol dehydrogenase pathway and converted to acetate under the control of aldehyde dehydrogenase. Thus its concentration can be influenced by the activity of both these enzymes, which are present in liver and other tissues. One might postulate that CPAF-positive subjects have either increased activity of alcohol dehydrogenase or decreased aldehyde dehydrogenase activity, or both, the second explanation being perhaps the more plausible as chlorpropamide has been shown to inhibit aldehyde dehydrogenase activity in vitro.'2
It is tempting to speculate that CPAF-positive subjects may have a genetically determined aldehyde dehydrogenase isoenzyme that is particularly susceptible to chlorpropamide inhibition.
